human primary peripheral blood cd4 t cells Search Results


human peripheral blood cd4 + t-cells  (STEMCELL Technologies Inc)
90
STEMCELL Technologies Inc human peripheral blood cd4 + t-cells
CBP/p300 inhibition induces HIV-1 expression in <t>CD4</t> + cells ex vivo (A) Experimental design for RGH infection of primary CD4 + T cells. CD4 + T cells isolated from an uninfected participant were infected with the RGH dual reporter virus at a low MOI. 3 days, post-infection, cells were incubated with a vehicle control (DMSO), 10 μM A-485, or 10 μM iP300w for 24 h after which proviral expression was assessed by flow cytometry. (B) Representative flow cytometry scatterplots of primary CD4 + T cells treated as in (A). Latent infections are in Q1 (mCherry+), productively infected T cells are in Q2 (GFP+/mCherry+), noise generated by viral recombination is in Q3 (GFP+), and uninfected cells are in Q4. (C and D) Following treatment of primary CD4 + T cells as in (A), proviral transcription was determined by flow cytometry and is expressed as the percentage of productive infections (C) and the GFP mean fluorescence intensity (MFI) of infected cells (D) ( n = 3, mean ± SD, one-way ANOVA with Dunnett’s multiple comparisons test). (E) Viability was determined for participant derived CD4 + T cells treated as in (A) ( n = 3, mean ± SD, one-way ANOVA with Dunnett’s multiple comparisons test). (F and G) Primary CD4 + PBMCs isolated from people living with HIV-1 who are receiving ART were treated with a vehicle (DMSO), 10 μM A-485, or 10 μM iP300w and were either left unstimulated or were treated with anti-CD3/anti-CD28. Following 24 h, intracellular RNA was extracted, and RT-PCR was preformed using oligos specific for multiply spliced Tat-Rev HIV-1 mRNA transcripts. HIV-1 mRNA expression is normalized to GAPDH ( n = 3, mean ± SD, unpaired t test). (H) Primary CD4 + PBMCs treated as in (F) and (G) were assessed for cellular viability ( n = 2, mean, unpaired t test). Statistical significance is indicated at ∗ p < 0.05, ∗∗ p < 0.01, or ∗∗∗ p < 0.001, with n.s. denoting non-significant p ≥ 0.05.
Human Peripheral Blood Cd4 + T Cells, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+primary+peripheral+blood+cd4+++t+cells/human+peripheral+blood+cd4++t+cells/pmc11617383-25-0-7
Average 90 stars, based on 1 article reviews
human peripheral blood cd4 + t-cells - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
serum sample cat # 200-0162  (STEMCELL Technologies Inc)
90
STEMCELL Technologies Inc serum sample cat # 200-0162
CBP/p300 inhibition induces HIV-1 expression in <t>CD4</t> + cells ex vivo (A) Experimental design for RGH infection of primary CD4 + T cells. CD4 + T cells isolated from an uninfected participant were infected with the RGH dual reporter virus at a low MOI. 3 days, post-infection, cells were incubated with a vehicle control (DMSO), 10 μM A-485, or 10 μM iP300w for 24 h after which proviral expression was assessed by flow cytometry. (B) Representative flow cytometry scatterplots of primary CD4 + T cells treated as in (A). Latent infections are in Q1 (mCherry+), productively infected T cells are in Q2 (GFP+/mCherry+), noise generated by viral recombination is in Q3 (GFP+), and uninfected cells are in Q4. (C and D) Following treatment of primary CD4 + T cells as in (A), proviral transcription was determined by flow cytometry and is expressed as the percentage of productive infections (C) and the GFP mean fluorescence intensity (MFI) of infected cells (D) ( n = 3, mean ± SD, one-way ANOVA with Dunnett’s multiple comparisons test). (E) Viability was determined for participant derived CD4 + T cells treated as in (A) ( n = 3, mean ± SD, one-way ANOVA with Dunnett’s multiple comparisons test). (F and G) Primary CD4 + PBMCs isolated from people living with HIV-1 who are receiving ART were treated with a vehicle (DMSO), 10 μM A-485, or 10 μM iP300w and were either left unstimulated or were treated with anti-CD3/anti-CD28. Following 24 h, intracellular RNA was extracted, and RT-PCR was preformed using oligos specific for multiply spliced Tat-Rev HIV-1 mRNA transcripts. HIV-1 mRNA expression is normalized to GAPDH ( n = 3, mean ± SD, unpaired t test). (H) Primary CD4 + PBMCs treated as in (F) and (G) were assessed for cellular viability ( n = 2, mean, unpaired t test). Statistical significance is indicated at ∗ p < 0.05, ∗∗ p < 0.01, or ∗∗∗ p < 0.001, with n.s. denoting non-significant p ≥ 0.05.
Serum Sample Cat # 200 0162, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+primary+peripheral+blood+cd4+++t+cells/human+primary+peripheral+blood+CD4++T+cells+Cat++++200+0165/pmc11490487-339-8-13
Average 90 stars, based on 1 article reviews
serum sample cat # 200-0162 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
primary human peripheral blood-derived cd4+ t cells stem cell  (STEMCELL Technologies Inc)
90
STEMCELL Technologies Inc primary human peripheral blood-derived cd4+ t cells stem cell
In vitro treatment of activated <t>CD4+</t> T cells with Y201 and Y202 EVs (n=2, mean events >18,000 counted) A) Proliferative cycles. B) Proliferative index C) Polarisation of activated T cells in the absence and presence of Y201 EVs and Y202 EVs (n=2, mean events >32,000 counted). D/E) Total peritoneal exudate cell (PEC) counts following zymosan (D) or schistosome egg (E) induced inflammation in the absence and presence of Y201 EVs and Y202 EVs. F/G) Examination of TCR+CD4+, naïve and central memory T cells in zymosan or schistosome egg induced inflammation in the absence and presence of Y201 EVs and Y202 EVs (n=3). One-Way ANOVA with Bonferroni post hoc testing,*p<0.05, **p<0.01, ***p<0.001.
Primary Human Peripheral Blood Derived Cd4+ T Cells Stem Cell, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+primary+peripheral+blood+cd4+++t+cells/primary+human+peripheral+blood+derived+cd4++t+cells+stem+cell/bio_rxiv__2024__09__05__609844-177-22-25
Average 90 stars, based on 1 article reviews
primary human peripheral blood-derived cd4+ t cells stem cell - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
human peripheral blood cd4+ t cells, cryopreserved  (Lonza)
N/A
Cryopreserved ampule of Human Peripheral Blood CD4+ T Cells containing ≥10 million cells
   Buy from Supplier
human peripheral blood cd4+ t helper cells  (AcceGen Biotechnology)
N/A
Human Peripheral Blood Mononuclear Cells are available as positive and negative controls for T-cell monitoring in ELISPOT, ELISA, cytokine bead array, tetramer/pentamer, and flow cytometry assays.
   Buy from Supplier

Image Search Results


CBP/p300 inhibition induces HIV-1 expression in CD4 + cells ex vivo (A) Experimental design for RGH infection of primary CD4 + T cells. CD4 + T cells isolated from an uninfected participant were infected with the RGH dual reporter virus at a low MOI. 3 days, post-infection, cells were incubated with a vehicle control (DMSO), 10 μM A-485, or 10 μM iP300w for 24 h after which proviral expression was assessed by flow cytometry. (B) Representative flow cytometry scatterplots of primary CD4 + T cells treated as in (A). Latent infections are in Q1 (mCherry+), productively infected T cells are in Q2 (GFP+/mCherry+), noise generated by viral recombination is in Q3 (GFP+), and uninfected cells are in Q4. (C and D) Following treatment of primary CD4 + T cells as in (A), proviral transcription was determined by flow cytometry and is expressed as the percentage of productive infections (C) and the GFP mean fluorescence intensity (MFI) of infected cells (D) ( n = 3, mean ± SD, one-way ANOVA with Dunnett’s multiple comparisons test). (E) Viability was determined for participant derived CD4 + T cells treated as in (A) ( n = 3, mean ± SD, one-way ANOVA with Dunnett’s multiple comparisons test). (F and G) Primary CD4 + PBMCs isolated from people living with HIV-1 who are receiving ART were treated with a vehicle (DMSO), 10 μM A-485, or 10 μM iP300w and were either left unstimulated or were treated with anti-CD3/anti-CD28. Following 24 h, intracellular RNA was extracted, and RT-PCR was preformed using oligos specific for multiply spliced Tat-Rev HIV-1 mRNA transcripts. HIV-1 mRNA expression is normalized to GAPDH ( n = 3, mean ± SD, unpaired t test). (H) Primary CD4 + PBMCs treated as in (F) and (G) were assessed for cellular viability ( n = 2, mean, unpaired t test). Statistical significance is indicated at ∗ p < 0.05, ∗∗ p < 0.01, or ∗∗∗ p < 0.001, with n.s. denoting non-significant p ≥ 0.05.

Journal: iScience

Article Title: CBP/p300 lysine acetyltransferases inhibit HIV-1 expression in latently infected T cells

doi: 10.1016/j.isci.2024.111244

Figure Lengend Snippet: CBP/p300 inhibition induces HIV-1 expression in CD4 + cells ex vivo (A) Experimental design for RGH infection of primary CD4 + T cells. CD4 + T cells isolated from an uninfected participant were infected with the RGH dual reporter virus at a low MOI. 3 days, post-infection, cells were incubated with a vehicle control (DMSO), 10 μM A-485, or 10 μM iP300w for 24 h after which proviral expression was assessed by flow cytometry. (B) Representative flow cytometry scatterplots of primary CD4 + T cells treated as in (A). Latent infections are in Q1 (mCherry+), productively infected T cells are in Q2 (GFP+/mCherry+), noise generated by viral recombination is in Q3 (GFP+), and uninfected cells are in Q4. (C and D) Following treatment of primary CD4 + T cells as in (A), proviral transcription was determined by flow cytometry and is expressed as the percentage of productive infections (C) and the GFP mean fluorescence intensity (MFI) of infected cells (D) ( n = 3, mean ± SD, one-way ANOVA with Dunnett’s multiple comparisons test). (E) Viability was determined for participant derived CD4 + T cells treated as in (A) ( n = 3, mean ± SD, one-way ANOVA with Dunnett’s multiple comparisons test). (F and G) Primary CD4 + PBMCs isolated from people living with HIV-1 who are receiving ART were treated with a vehicle (DMSO), 10 μM A-485, or 10 μM iP300w and were either left unstimulated or were treated with anti-CD3/anti-CD28. Following 24 h, intracellular RNA was extracted, and RT-PCR was preformed using oligos specific for multiply spliced Tat-Rev HIV-1 mRNA transcripts. HIV-1 mRNA expression is normalized to GAPDH ( n = 3, mean ± SD, unpaired t test). (H) Primary CD4 + PBMCs treated as in (F) and (G) were assessed for cellular viability ( n = 2, mean, unpaired t test). Statistical significance is indicated at ∗ p < 0.05, ∗∗ p < 0.01, or ∗∗∗ p < 0.001, with n.s. denoting non-significant p ≥ 0.05.

Article Snippet: Human Peripheral Blood CD4 + T-cells , StemCell Technologies , 200–0165.

Techniques: Inhibition, Expressing, Ex Vivo, Infection, Isolation, Virus, Incubation, Control, Flow Cytometry, Generated, Fluorescence, Derivative Assay, Reverse Transcription Polymerase Chain Reaction

Journal: iScience

Article Title: CBP/p300 lysine acetyltransferases inhibit HIV-1 expression in latently infected T cells

doi: 10.1016/j.isci.2024.111244

Figure Lengend Snippet:

Article Snippet: Human Peripheral Blood CD4 + T-cells , StemCell Technologies , 200–0165.

Techniques: Virus, Recombinant, SYBR Green Assay, Activation Assay

In vitro treatment of activated CD4+ T cells with Y201 and Y202 EVs (n=2, mean events >18,000 counted) A) Proliferative cycles. B) Proliferative index C) Polarisation of activated T cells in the absence and presence of Y201 EVs and Y202 EVs (n=2, mean events >32,000 counted). D/E) Total peritoneal exudate cell (PEC) counts following zymosan (D) or schistosome egg (E) induced inflammation in the absence and presence of Y201 EVs and Y202 EVs. F/G) Examination of TCR+CD4+, naïve and central memory T cells in zymosan or schistosome egg induced inflammation in the absence and presence of Y201 EVs and Y202 EVs (n=3). One-Way ANOVA with Bonferroni post hoc testing,*p<0.05, **p<0.01, ***p<0.001.

Journal: bioRxiv

Article Title: Extracellular vesicle bioactivity and potential clinical utility is determined by mesenchymal stromal cell clonal subtype

doi: 10.1101/2024.09.05.609844

Figure Lengend Snippet: In vitro treatment of activated CD4+ T cells with Y201 and Y202 EVs (n=2, mean events >18,000 counted) A) Proliferative cycles. B) Proliferative index C) Polarisation of activated T cells in the absence and presence of Y201 EVs and Y202 EVs (n=2, mean events >32,000 counted). D/E) Total peritoneal exudate cell (PEC) counts following zymosan (D) or schistosome egg (E) induced inflammation in the absence and presence of Y201 EVs and Y202 EVs. F/G) Examination of TCR+CD4+, naïve and central memory T cells in zymosan or schistosome egg induced inflammation in the absence and presence of Y201 EVs and Y202 EVs (n=3). One-Way ANOVA with Bonferroni post hoc testing,*p<0.05, **p<0.01, ***p<0.001.

Article Snippet: To determine MSC-derived EV immunomodulation for deactivation and suppression of T cell proliferation, suspension cultures of 1.0×10 5 primary human peripheral blood-derived CD4+ T cells (Stem Cell Technologies) were grown in RPMI-1640 with 10% FBS 1% P/S (Gibco, Cat: 10363083) and were pre-treated for 6hrs with 20X EVs isolated from serum-free conditioned medium collected over 24hrs culture from 2.0×10 6 of Y201 or Y202 MSCs.

Techniques: In Vitro